Skip to content

Newsroom

type
year
Illustration image.png

Statutory negotiations at Orion's R&D unit in Turku, Finland have been concluded

4/15/2025 Press release
Illustration image.png

Orion publishes Interim Report for January–March 2025 and holds a webcast on 23 April 2025

4/9/2025 Press release
Illustration image.png

Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 

3/21/2025 Press release
Illustration image.png

Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku

3/10/2025 Press release
Illustration image.png

Orion and Aiforia extend collaboration to preclinical study evaluations

3/5/2025 Press release
Illustration image.png

EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability

2/13/2025 Press release
Illustration image.png

Save the Date: Orion’s Capital Markets Day on 22 May 2025

2/10/2025 Press release
Illustration image.png

Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics

1/30/2025 Press release
Illustration image.png

Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025

1/28/2025 Press release
Illustration image.png

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

1/7/2025 Press release
Illustration image.png

Orion and Marinus terminate agreement for ganaxolone in Europe

12/30/2024 Press release
Illustration image.png

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

12/18/2024 Press release
Illustration image.png

Orion Research Foundation grants EUR 1,109,000 for research in 2025

11/22/2024 Press release
Illustration image.png

Orion and Alligator Bioscience amend their agreement concerning two bispecific antibodies

11/19/2024 Press release
Illustration image.png

Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024

10/15/2024 Press release
Illustration image.png

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

10/14/2024 Press release
Illustration image.png

Orion’s near-term climate targets approved by the Science Based Targets initiative

9/30/2024 Press release
Illustration image.png

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

9/26/2024 Press release